About iSTAR Medical

iSTAR Medical SA, founded in 2011 and headquartered in Wavre, Belgium, is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally.

iSTAR Medical head offices

iSTAR Medical has exclusive rights to the STAR® biomaterial from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the treatment of glaucoma. The fast-growing glaucoma surgical device market is expected to reach $1.84 bn worldwide by 2025.*

iSTAR Medical’s management team and board have a successful track record in end-to-end product development, with proven clinical, regulatory and market access capabilities. The company is backed by specialised institutional and private investors.

SRIW
BioWin
Emertec
Namur
DGO
sfpi fpim
Nivel
Gimv
LSP
Earlybird

* Glaucoma Surgical Device Market Report, Market Scope 2020